Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
Fushouyuan (01448.HK) remains suspended on the Hong Kong Exchange; the stock will be removed from the Hang Seng Index (HSI) series.
2026-06-22
Fushouyuan (01448.HK) remains suspended on the Hong Kong Exchange; the stock will be removed from the Hang Seng Index (HSI) series.
Back
Other News
2026-06-22
Israel and Lebanon will hold talks this week to discuss transferring control of relevant areas to the Lebanese army.
Israel and Lebanon will hold talks this week to discuss transferring control of relevant areas to the Lebanese army.
2026-06-22
The National Medical Products Administration, via its priority review channel, has granted conditional approval to Chengdu Bailiduote Biopharma Co., Ltd.'s injectable monoclonal antibody Lunkangyilongtuo (trade name Yizekang). Indication: adults with
The National Medical Products Administration, via its priority review channel, has granted conditional approval to Chengdu Bailiduote Biopharma Co., Ltd.'s injectable monoclonal antibody Lunkangyilongtuo (trade name Yizekang). Indication: adults with recurrent or metastatic nasopharyngeal carcinoma who progressed after at least two lines of systemic chemotherapy and prior PD‑1/PD‑L1 inhibitor therapy. The approval adds a new treatment option for this patient cohort.
Chat with us
, powered by
LiveChat